Lupin and Sandoz Sign Licensing Deal for Biosimilar Ranibizumab Across Multiple Regions

Lupin and Sandoz Group AG have entered into a licensing agreement under which Sandoz will market and commercialize Lupin’s biosimilar ranibizumab in several key global markets.

Agreement Scope and Regional Rights

Under the terms of the agreement, Sandoz will handle commercialization in the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.

While Sandoz will oversee marketing and commercialization, Lupin will retain responsibility for manufacturing and regulatory submissions.

       • In all territories except France, Australia, Vietnam, and Malaysia, Sandoz will hold exclusive marketing rights.

       • In France, Australia, Vietnam, and Malaysia, Sandoz will have semi-exclusive marketing rights.

About Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and choroidal neovascularization (CNV).

Strategic Rationale and Leadership Perspective

“We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally. This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients,” said Thierry Volle, President EMEA and Emerging Markets at Lupin.

Canadian Commercialization Rights

In a separate agreement, Sandoz will receive sole commercialization rights for Lupin’s biosimilar ranibizumab in Canada, while Lupin will continue to manage manufacturing and regulatory filings.